Nika Pharmaceuticals Inc. (NIKA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $369M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNika Pharmaceuticals Inc. (NIKA) trades at $0.35. Nika Pharmaceuticals, Inc. focuses on developing drugs for various diseases, including HIV/AIDS and cancer. Market cap: $369M, Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for NIKA: NIKA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Nika Pharmaceuticals Inc. (NIKA) Healthcare & Pipeline Overview
Nika Pharmaceuticals, Inc., based in Henderson, Nevada, develops and markets drugs and supplements targeting HIV/AIDS, hepatitis, rheumatoid arthritis, cancer, and diabetes. With a high profit margin despite a negative P/E ratio, the company operates in the competitive specialty and generic drug manufacturing industry, facing both opportunities and challenges in the OTC market.
What Is the Investment Thesis for NIKA?
Nika Pharmaceuticals presents a high-risk, high-reward investment profile. The company's extremely high profit margin of 33191.0% suggests potential profitability if revenue scales, but the negative P/E ratio of -15172.39 indicates current losses. Growth catalysts include potential FDA approvals for its drug pipeline and expansion into new therapeutic areas. However, the company's OTC listing and negative beta of -1.61 highlight volatility and market sensitivity. Investors should carefully assess the company's financial stability, regulatory risks, and competitive positioning before considering an investment. Success hinges on Nika's ability to successfully commercialize its drug candidates and achieve sustainable profitability.
Based on FMP financials and quantitative analysis
NIKA Key Highlights
Market Cap of $369M indicates the company's current valuation in the OTC market.
- P/E Ratio of -15172.39 reflects current losses and high investor expectations for future earnings.
- Profit Margin of 33191.0% suggests significant potential for profitability if revenue scales effectively.
- Gross Margin of 100.0% indicates efficient cost management in the production of its products.
- Beta of -1.61 suggests the stock price moves inversely to the market, potentially offering diversification benefits but also indicating higher risk.
Who Are NIKA's Competitors?
NIKA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BHCCF Benchmark Holdings plc | $0.37 | 0.00% | $225M | — |
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $252M | — |
| COGZF Cogstate Limited | $2.43 | 0.00% | $419M | — |
| EMBC Embecta Corp. | $6.19 | +1.64% | $351M | 71 5-pillar |
| TLRY Tilray Brands, Inc. | $2.07 | -8.00% | $306M | — |
| SNDL SNDL Inc. | $1.24 | -7.46% | $302M | 32 5-pillar |
| EOLS Evolus, Inc. | $7.00 | -0.99% | $463M | — |
| KMDA Kamada Ltd. | $8.07 | -1.10% | $466M | 87 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NIKA's Key Strengths?
High profit margin (33191.0%) indicates potential for profitability.
- Diverse product pipeline targeting multiple diseases.
- Proprietary drug formulations.
- Established presence in the dietary supplement market.
What Are NIKA's Weaknesses?
Negative P/E ratio (-15172.39) indicates current losses.
- OTC listing suggests higher risk and lower liquidity.
- Limited financial resources compared to larger competitors.
- Dependence on successful drug development and regulatory approvals.
What Could Drive NIKA Stock Higher?
Potential FDA approval for new drug candidates in the pipeline.
- Expansion into new geographic markets.
- Strategic partnerships and collaborations with other pharmaceutical companies.
- Development of biosimilar drugs.
- Research and development of personalized medicine approaches.
What Are the Key Risks for NIKA?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for new drug candidates.
- Competition from larger, more established pharmaceutical companies.
- Patent expirations and generic competition.
- Stringent regulatory requirements and potential delays in drug approvals.
- Product liability lawsuits.
What Are the Growth Opportunities for NIKA?
- Expansion of Product Portfolio: Nika can expand its product portfolio by developing and commercializing new drugs for its existing therapeutic areas, such as HIV/AIDS, hepatitis, rheumatoid arthritis, cancer, and diabetes. The global market for these diseases is substantial, offering significant revenue potential. Successful development and approval of new drugs could drive significant revenue growth for Nika over the next 3-5 years.
- Strategic Partnerships and Acquisitions: Nika can pursue strategic partnerships and acquisitions to expand its product pipeline, access new technologies, and enter new markets. Collaborating with other pharmaceutical companies or acquiring smaller biotech firms could accelerate Nika's growth and enhance its competitive position. These partnerships can be established within the next 1-2 years.
- Geographic Expansion: Nika can expand its geographic reach by entering new markets, particularly in developing countries where there is a growing demand for affordable medicines. Expanding into new markets could significantly increase Nika's revenue and profitability over the next 3-5 years. This expansion requires navigating regulatory hurdles and establishing distribution networks.
- Development of Biosimilars: Nika can capitalize on the growing biosimilars market by developing and commercializing biosimilar versions of existing biologic drugs. The biosimilars market is expected to grow significantly in the coming years as patents for biologic drugs expire. Nika can launch its first biosimilar product within the next 2-3 years.
- Focus on Personalized Medicine: Nika can invest in personalized medicine approaches, such as developing targeted therapies based on individual patient characteristics. Personalized medicine is a rapidly growing field with the potential to revolutionize healthcare. Nika can begin clinical trials for personalized medicine within the next 3-4 years.
What Are NIKA's Competitive Advantages?
- Proprietary drug formulations.
- Patents protecting its key products.
- Established relationships with distributors.
- Brand recognition in specific therapeutic areas.
What Does NIKA Do?
Nika Pharmaceuticals, Inc., incorporated in 2000 and based in Henderson, Nevada, is a pharmaceutical company focused on developing treatments for a range of diseases, including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. Originally named Centennial Growth Equities Inc., the company rebranded to Nika Pharmaceuticals, Inc. in May 2022, signaling a strategic shift towards pharmaceutical development. Nika's product offerings include dietary supplements, antiviral drugs, and thymus nuclear glycoprotein, primarily targeting HIV. The company operates within the specialty and generic drug manufacturing sector, navigating the complexities of drug development, regulatory approvals, and market competition. Nika's business model encompasses research, development, and commercialization of pharmaceutical products, with a focus on addressing unmet medical needs in its target therapeutic areas. The company aims to provide accessible and effective treatments, contributing to improved patient outcomes and overall healthcare advancement. Nika Pharmaceuticals operates primarily in the United States, with potential for future expansion into international markets.
What Products and Services Does NIKA Offer?
- Develops drugs for the treatment of HIV/AIDS.
- Develops drugs for the treatment of hepatitis B and C.
- Develops drugs for the treatment of rheumatoid arthritis.
- Develops drugs for the treatment of cancer.
- Develops drugs for the treatment of diabetes.
- Offers dietary supplements.
- Offers antiviral drugs.
- Provides thymus nuclear glycoprotein for the treatment of HIV.
How Does NIKA Make Money?
- Develops and patents pharmaceutical products.
- Manufactures or outsources the manufacturing of its drugs.
- Markets and sells its products through distributors and direct sales.
- Generates revenue from the sale of its pharmaceutical products and supplements.
What Industry Does NIKA Operate In?
Nika Pharmaceuticals operates in the specialty and generic drug manufacturing industry, a sector characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. Nika competes with larger, more established pharmaceutical companies, including ABTI, BHCCF, BHHKF, CMVLF, and COGZF, as well as smaller biotech firms. Success in this industry requires significant investment in research and development, a strong intellectual property portfolio, and effective marketing and distribution strategies.
Who Are NIKA's Key Customers?
- Patients suffering from HIV/AIDS.
- Patients suffering from hepatitis B and C.
- Patients suffering from rheumatoid arthritis.
- Patients suffering from cancer.
- Patients suffering from diabetes.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
How Nika Pharmaceuticals Inc. Is Valued
Nika Pharmaceuticals Inc. carries a market capitalization of $369M, placing it in the small-cap category.
Company Profile
Nika Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Dimitar Slavchev Savov. NIKA has traded publicly since 2024.
Key Financial Metrics
Return on equity for Nika Pharmaceuticals Inc. stands at 25.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Nika Pharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NIKA Financials
Bull Case vs Bear Case
Bull Case
- High profit margin (33191.0%) indicates potential for profitability.
- Diverse product pipeline targeting multiple diseases.
- Proprietary drug formulations.
- Established presence in the dietary supplement market.
Bear Case
- Negative P/E ratio (-15172.39) indicates current losses.
- OTC listing suggests higher risk and lower liquidity.
- Limited financial resources compared to larger competitors.
- Dependence on successful drug development and regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NIKA Latest News
No recent news available for NIKA.
NIKA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NIKA.
Price Targets
Wall Street price target analysis for NIKA.
NIKA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NIKA; grades run from A+ (80-100) to F (below 30).
Leadership: Dimitar Slavchev Savov
CEO
Dimitar Slavchev Savov serves as the Chief Executive Officer of Nika Pharmaceuticals Inc. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial for guiding Nika Pharmaceuticals through the challenges and opportunities of the competitive pharmaceutical market.
Track Record: Information on Dimitar Slavchev Savov's specific achievements and strategic decisions at Nika Pharmaceuticals is not available. Assessing his track record requires further information on key milestones achieved under his leadership, such as successful drug development programs, regulatory approvals, and financial performance improvements. His tenure and impact on the company's growth trajectory remain to be evaluated based on future performance and available data.
NIKA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nika Pharmaceuticals may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures, be undergoing restructuring, or face regulatory issues. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in Nika Pharmaceuticals.
- OTC Tier: OTC Other
- Limited financial disclosures and transparency.
- Higher risk of fraud and manipulation.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting or trading suspension.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2000.
- Development of drugs for serious diseases like HIV/AIDS and cancer.
- Presence in the dietary supplement market.
- Change of name in 2022 to reflect focus on pharmaceuticals.
What Investors Ask About Nika Pharmaceuticals Inc. (NIKA) — Healthcare
Is NIKA a good stock to buy?
Stock Expert AI does not rate NIKA buy, sell or hold. Nika Pharmaceuticals Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NIKA stock price today?
The last price recorded on this page for Nika Pharmaceuticals Inc. (NIKA) is $0.35, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Nika Pharmaceuticals Inc. do?
Nika Pharmaceuticals Inc. is a pharmaceutical company that develops, manufactures, and markets drugs and supplements. Their primary focus is on treatments for diseases such as HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes.
What are the key factors to evaluate for NIKA?
Evaluate NIKA on fundamentals, analyst consensus, and risk factors. Market Cap of $369M indicates the company's current valuation in the OTC market. Not financial advice.
How frequently does NIKA data refresh on this page?
NIKA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NIKA's recent stock price performance?
Nika Pharmaceuticals Inc. (NIKA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margin (33191.0%) indicates potential for profitability. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NIKA overvalued or undervalued right now?
Nika Pharmaceuticals Inc. (NIKA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NIKA before investing?
Before investing in Nika Pharmaceuticals Inc. (NIKA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available on CEO track record.
- OTC market data may be less reliable than exchange-listed data.